Candriam S.C.A. Essa Pharma Inc. Transaction History

Candriam S.C.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$1.75 - $3.44 $262,169 - $515,349	-149,811 Reduced 26.41%	417,532 $760,000
Q2 2022 Aug 03, 2022	SELL	$3.15 - $7.94 $65,283 - $164,556	-20,725 Reduced 3.52%	567,343 $1.79 Million
Q1 2022 May 13, 2022	SELL	$6.18 - $14.44 $236,125 - $551,723	-38,208 Reduced 6.1%	588,068 $3.63 Million
Q4 2021 Feb 10, 2022	BUY	$7.8 - $14.38 $2.54 Million - $4.68 Million	325,751 Added 108.39%	626,276 $8.89 Million
Q2 2021 Jul 20, 2021	BUY	$24.17 - $34.28 $7.26 Million - $10.3 Million	300,508 Added 1767694.12%	300,525 $8.59 Million
Q1 2021 Apr 29, 2021	BUY	$11.61 - $32.08 $197 - $545	17 New	17 $0

35.1M

15.8K

21K

Ticker EPIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,073,100
Market Cap $75.4M
Description
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreem...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.